Fredun Pharmaceuticals Performance
Fundamentals of Fredun Pharmaceuticals
|P/E Ratio (TTM)||NA|
|Debt to Equity||NA|
Financials of Fredun Pharmaceuticals
Financials data is not available for Fredun Pharmaceuticals. Please visit after some time.
About Fredun Pharmaceuticals
Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals (FPL) was converted into a public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora ... . The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems. The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind. In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden. Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka. In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category. Read More
|Stocks||Market Cap (cr)||Market Price (₹)||52 Week Low-High (₹)|
|Supriya Lifescience Ltd||₹2,231.79||
|274.8 - 279.5|
|Celestial Biolabs Ltd||₹4.56||
|1.75 - 1.8|
|JFL Life Sciences Ltd||₹48.94||
|43.95 - 44.5|
|Procter & Gamble Health Ltd||₹8,424.50||
|4981.7 - 5099.95|
|Veerhealth Care Ltd||₹33.64||
|26 - 26|
What is the Share price of Fredun Pharmaceuticals ()?
Can I buy Fredun Pharmaceuticals () shares?
How do I buy Fredun Pharmaceuticals () from Angel One?
- Direct investment: You can buy Fredun Pharmaceuticals () shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Fredun Pharmaceuticals () shares.